Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.41 |
| ▸ | ITGAV | P06756 | 14/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211687 | 0.86 | ITGB3 (0.53) | ITGB3ITGAVCTSLCTSBCTSK | |
| SCHEMBL7212726 | 0.82 | ITGB3 (0.53) | ITGB3ITGAV | |
| Acetic Acid SCHEMBL7217682 | 0.70 | ITGB3 (0.40) | ITGB3ITGAVCTSLCTSBCTSK | |
| SCHEMBL7211696 | 0.69 | ITGB3 (0.35) | ITGB3ITGAVCTSLCTSBCTSK | |
| SCHEMBL7211331 | 0.69 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL7217721 | 0.68 | ITGB3 (0.70) | ITGB3ITGAV | |
| SCHEMBL7445939 | 0.63 | ITGB3 (0.45) | ITGB3ITGAVCTSLCTSBCTSK | |
| SCHEMBL7211353 | 0.63 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL7980895 | 0.63 | PLG (0.45) | ITGB3ITGAVCTSLCTSKCTSS | |
| SCHEMBL7211492 | 0.63 | ITGB3 (0.53) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | WEHNER VOLKMAR (DE) | 2001-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885CTSL 761/4885 |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885CTSL 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.